Dr. Scapin to continue her leadership and advancement of Garuda’s platform technology for generating self-renewing blood stem cells

CAMBRIDGE, Mass. July 12, 2023 – Garuda Therapeutics announced the appointment of Giorgia Scapin, Ph.D., as Chief Scientific Officer. Transitioning from her previous role as Senior Vice President of Research and Development at Garuda, Dr. Scapin will oversee the company’s scientific strategy and lead the advancement of Garuda’s off-the-shelf hematopoietic stem cell (HSC) therapies in her new role as Chief Scientific Officer. read more →

Partnership has potential to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies

MINNEAPOLIS, May 24, 2023 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced a working partnership with Garuda Therapeutics, a company working to create off-the-shelf, durable blood stem cell-based cellular therapies. read more →

One cell therapy to treat them all – or at least 120-plus different diseases. Garuda Therapeutics closed a $62 million Series B round Tuesday to support its off-the-shelf, self-renewing blood stem cell technology.

Using a patient’s own depleted cells or seeking out a biological donor match is both costly and time prohibitive. Garuda’s proprietary hematopoietic stem cells could be the industry’s first off-the-shelf offering, leading to faster, more effective treatments and greater patient accessibility. read more →

The science that led Garuda Therapeutics Inc. to a $62 million series B financing was a combination of hard work, luck and serendipity, according to co-founder and CEO Dhvanit Shah.

At the Harvard Stem Cell Institute, Shah and his fellow researchers found that endothelial cells go through significant modifications before becoming hematopoietic stem cells. That simple discovery, as Shah told BioWorld, brought on research leading to the possibility that patients would not need a marrow donor before receiving a stem cell treatment. read more →

Fifteen months after launching with $72 million and a mission to treat 70 different diseases with stem cell-based drugs, Garuda Therapeutics has raised another $62 million and now says it’s looking at 120 potential target diseases.

Garuda announced the new funding on Tuesday morning. Backing the Series B round are lead investors Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management and Aisling Capital, with participation from Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments and others. read more →

Garuda Therapeutics brought in $62 million via a Series B to take its off-the-shelf cell therapies into the clinic next year.

The Boston-area biotech wants to rid the need for blood stem cell transplants and instead give patients self-renewing blood stem cells. The proceeds, which add to a $72 million Series A from September 2021, will bankroll two lead programs in hematological and oncology indications, Garuda said Tuesday morning. read more →

CAMBRIDGE, Mass. – February 7, 2023 – -Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B financing led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital, along with participation from Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments, and other elite investors and individuals. read more →

CAMBRIDGE, Mass. – January 5, 2023 – -Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 4:30pm PT / 7:30pm ET. read more →

CAMBRIDGE, Mass. – September 7, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of Roger Sawhney, M.D., as Chief Financial Officer. Dr. Sawhney previously served as Chief Financial Officer and Chief Business Officer at Omega Therapeutics, a pioneer in mRNA-based therapeutics for precision gene modulation. read more →

CAMBRIDGE, Mass. – March 15, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of James Desiderio, Ph.D. as Chief Regulatory Officer. Dr. Desiderio previously served as Senior Vice President of Regulatory Affairs and Quality at Acceleron Pharma. read more →

CAMBRIDGE, Mass. – January 6, 2022 – Garuda Therapeutics (Garuda), today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 (Tuesday) at 5:30 pm EST. read more →

CAMBRIDGE, Mass. – January 5, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of Laurence Reid, Ph.D. to its board of directors… read more →

“Look at that! Life!” said Deidra Flowers-Williams, a sickle cell disease patient, as she held up a tube with stem cells donated by her sister, Tanisha Flowers. It was just minutes before doctors at the NIH Clinical Center… read more →

CAMBRIDGE, Mass. – September 23, 2021 – Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, launched today with an oversubscribed $72 million Series A financing … read more →

One platform, 70 diseases and $72 million — these underpin the launch of Garuda Therapeutics, a new stem cell startup founded by Harvard professor Dhvanit Shah… read more →

We know blood stem cell transplants are potential cures for serious diseases. The problem is, patients need cells from immune-compatible donors, creating a supply bottleneck that constrains use in some areas and blocks expansion into new diseases. Garuda Therapeutics thinks it may have… read more →

A stem cell researcher who spent time at the Harvard Stem Cell Institute, the Broad Institute and Brigham and Women’s Hospital launched a new biotech Thursday, and he’s attracted significant blue-chip investment to get things up and running…. read more →